Research & Development
AtriCure closes acquisition of SentreHEART
14 August 2019 -

AtriCure Inc (Nasdaq:ATRC) on Tuesday reported the completion of the acquisition of SentreHEART Inc for an undisclosed amount.

Based in Redwood City, California, SentreHEART is a privately-owned medical device company committed to clinical evidence development and is currently sponsoring the FDA-approved prospective, multi-centre, randomized controlled trial (aMAZE Trial).

Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the left atrial appendage (LAA).

According to AtriCure Inc, it provides innovative technologies for the treatment of Afib and related conditions. The electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.

Login
Username:

Password:


Related Headlines

Johnson & Johnson to supply 100m doses of investigational COVID-19 vaccine to the US Government

FDA Grants Inhaled Use IND for RLF-100 to Treat Patients with Moderate and Severe COVID-19 Aiming to Prevent Progression to Respiratory Failure

Fujirebio Diagnostics Starts Clinical Testing for the Fully Automated Lumipulse SARS CoV-2 Antigen Assay

Eurofins Clinical Diagnostics Launches Lower Cost Highly Accurate COVID-19 PCR Test

Vela Diagnostics awarded FDA's EUA for the ViroKey SARS-CoV-2 RT-PCR Test

NeuroRx and Relief Therapeutics Holdings receive Investigational New Drug approval to test RLF-100

Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis

US Food and Drug Administration Fast Track Designation for delgocitinib Cream for the Treatment of Adults with Moderate-to-Severe Chronic Hand Eczema

FDA Fast Track Designation Granted to Sisunatovir for the Treatment of Serious Respiratory Syncytial Virus Infection

Immune-Onc Therapeutics Awarded USD 2.14m National Cancer Institute SBIR Grant to Support Development of IO-202, a First-in-class Antibody Targeting LILRB4

Siemens Healthineers Obtains First FDA EUA for Semi-Quantitative Antibody Test

FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients

US FDA provides update on COVID-19 situation

Research Center of America announces recruitment of healthy workers for COVID-19 research clinical trial in the fight against the virus

Macrogen achieves CE-IVD certificate for export of COVID-19 test kit into Europe and several other countries